![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.155 | 3.43% | 4.675 | 4.35 | 5.00 | - | 25,623 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/4/2020 09:17 | Please share? | slinkyj | |
24/4/2020 09:10 | Sell thus stock tuday. Bad ting hapen 10.50 | akbar1 | |
24/4/2020 09:09 | In Wikki UK biotech firm Synairgen started conducting trials on IFN-?, a drug that was originally developed to treat COPD.[10] IFN-? will be included in the international Solidarity Trial in combination with the HIV drugs Lopinavir and Ritonavir.[30] | slinkyj | |
24/4/2020 08:53 | Bit of coverage in this is money https://www.thisismo | slinkyj | |
24/4/2020 08:50 | A trade of 81p went through. Probably a fat finger or wrong ticker. It happens | ![]() vitec | |
24/4/2020 08:48 | Hmm I just had an alert come through saying SNG broke 77? Did it spike this morning, have I missed something? | slinkyj | |
24/4/2020 08:43 | Just need some more institutions buying up these shares and a 10p spread,that will sort the day traders out! | ![]() 2nell | |
24/4/2020 08:41 | Nobby perhaps they dont have your average and deep pockets. | ![]() chinadog3 | |
24/4/2020 08:31 | Real two way pull this morning. It is beyond me why people think 64p is a good price to sell at. Hey ho each to their own.... | ![]() nobbygnome | |
24/4/2020 08:27 | Yes, strange. | ![]() grosstonnage | |
24/4/2020 08:22 | 81p?? Anyone else just see that? | ![]() likya123 | |
24/4/2020 08:20 | If they keep the spread wide, it should make sellers hesitant 😉 | ![]() makendon | |
24/4/2020 08:16 | The potential to reach millions worldwide for asthma and copd let alone covid...i like this. | ![]() p winky | |
24/4/2020 08:11 | From lse board.. People need to read the research undertaken by the University of Texas (put on this website by Jack). Interferon 1 much more effective against SARS COV2 than its predecessor SARS, due to difference in protein structure. | ![]() likya123 | |
24/4/2020 08:09 | Nobby, imagine what it will do when we're global news?! Word is spreading. | ![]() likya123 | |
24/4/2020 08:08 | Encouraging start this morning.... | ![]() nobbygnome | |
24/4/2020 08:04 | Toffee man yes I am interested in that, because my mum wouldn't want to go in hospital but she would be fine to use a nebuliser because she is used to them. 4872 | ![]() hazl | |
24/4/2020 07:56 | A must watch from yesterday if you haven't already seen. We are still a little under the radar but not for very much longer... | ![]() likya123 | |
24/4/2020 07:51 | From what I hear there is little danger that the vaccine trial will be speedy. Because of the danger of the virus, the participants will not be exposed to live virus on purpose but be allowed to pick up any virus naturally. So if lockdown continues and virus spread is maintained at less than 1, then it will be a slow process. | glennrcharles | |
24/4/2020 07:51 | That's looks like good news,but a small selection of patients, sng treatment will be earlier in the phase of the illness and should stop patients getting to the stage where that treatment is going to be needed hopefully | ![]() d1nga | |
24/4/2020 07:48 | This has already been discussed. SNG's Inhaled Intrferon B is to prevent the patient having to be put on a ventilator in the first place. Better that they don't deteriorate to ventilator stage by intervention with SNG's treatment first, which would remove the need for treatment afterward and remove the need for a ventilator completely. | ![]() jev1 | |
24/4/2020 07:41 | Forget Gilead...now MESOBLAST +38% its allogeneic cell therapy remestemcel-L was administered under emergency compassionate use to 12 ventilator-dependent patients at New York's Mount Sinai hospital in March and April. It reported an 83% survival rate in the patients compared with 12% in ventilator-dependent Covid-19 patients who didn't receive the treatment at two major referral hospital networks in New York during the same period. The company said nine of the 12 patients, who received two infusions of remestemcel-L within the first five days of emergency treatment, came off ventilator support within a median of 10 days. That compared with 9% of patients receiving standard treatment. | ![]() markinvestor | |
24/4/2020 01:20 | I am too a responder....being told to stay at home and run meetings on Webex is not my thing. :-)..although the meetings continue. | ![]() dovey21 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions